We use our innovative DNA synthesis technology to rapidly produce long, linear DNA without compromising accuracy or quality. Our customers use ENFINIA DNA directly in their synthetic biology workflows with minimal or no cloning. This saves them weeks or months of time compared to workflows using conventional fragments from other suppliers that are both shorter and lower quality.
ENFINIA DNA accelerates mRNA vaccine development workflows by eliminating the entire master cell bank and plasmid production workflow. Delivered in 6-8 business days already at the length and quality required for in vitro transcription, ENFINIA DNA can save up to 15 weeks of time and effort.LEARN MORE
Rapid access to high-accuracy long DNA for gene synthesis can help make your gene therapy platform scalable, robust, productive and simple. By delivering highly accurate linear synthetic DNA at lengths up to 7kb in just 7 days, cell and gene therapy programs can save 2-3 weeks with every order and over 3 months with every project by skipping early rounds of cloning and directly assembling custom expression cassettes into plasmids for downstream cell expansion.
Building large multi-trait DNA cassettes of lengths over 20kb for plant or seed engineering can take months when your build process starts with conventional low-quality gene fragments. Using ENFINIA DNA with unprecedented speed and accuracy, you can eliminate early rounds of assembly and cloning to cut the build time in half.LEARN MORE
The combination of synthetic biology and evolving cell-free technologies has shown promise as a core technology for just-in-time manufacturing of valuable small molecules, therapeutically relevant biologics, antibodies, cytokines, and more. Access to highly accurate longer synthetic DNA building blocks for gene synthesis can streamline the construction of multi-part programmable molecular circuits by removing early assembly and cloning steps – saving weeks if not months per project.
Evolution of DNA Supply, What Advances in DNA Synthesis will Unlock the Agile Development of Biology. Chris Ghadban, Principal of Alix Ventures, moderates a panel of guests including Matthew Hill, Founder and CEO of Elegen, Jacob Becraft, Co-Founder and CEO of Strand Therapeutics, Tim Lu, Co-founder and CEO of Senti Bio, Cristina Butterfield, Sr. Director of Biochemistry at Metagenomi, and Patrick Boyle, Organism Designer at Ginkgo Bioworks, to discuss how a better solution for DNA synthesis will enable synthetic biologists to realize the promise of programmable biology.WATCH VIDEO
Recorded at the BIO2023 International Convention, Julianna LeMieux, Deputy Editor and Chief of Genetic Engineering News moderates this discussion about the impacts and future of DNA synthesis and synthetic biology with industry thought leaders Matthew Hill, Founder and CEO of Elegen, Madoo Varma, VP of Business Development at DNA Script, Elaine Shapland, Sr. Director of Build Technology Development at Ginkgo Bioworks, and Daniel Arlo, CEO of Ansa.WATCH VIDEO
Update on the latest advancements of Elegen's products and technology, presented at the Synbiobeta 2023 conference, by Matthew Hill, Founder and CEO.WATCH VIDEO
The DNA synthesis landscape may be poised for a major shift as companies make improvements in DNA synthesis, assembly and purification. Several companies now offer DNA synthesized enzymatically, a method that not only works in aqueous solution, thus avoiding the array of toxic compounds that are used in the more conventional synthesis, but also can produce complex sequences that can’t be made by chemical synthesis. Other companies are improving the accuracy of the final product by optimizing the assembly and purification steps.READ MORE
With advanced technology and a growing understanding of the underlying biology, biotherapy development has evolved. Since 2010, investments in the field have grown and the number of therapies launched globally has tripled. According to McKinsey & Company, from 2019 to 2021, venture capitalists invested over $52 billion in therapeutic-based biotech companies, with investments more than doubling between 2019 and 2020. However, there are challenges to manufacturing patient-specific biotherapies in a timely manner; fast, reliable access to high-quality DNA remains a critical bottleneck that limits further progress.READ MORE
Elegen Founder and CEO, Matt Hill Discusses the DNA supply bottleneck that limits the progress of synthetic biology, thoughts on the future of synthetic biology, and Elegen\'s unique approach to rapidly synthesizing long double-stranded linear DNA with high accuracy.LISTEN
Latest FORBES article from SynBioBeta CEO John Cumbers discussing the DNA supply bottleneck that is holding back the field of synthetic biology and how Elegen's unique and innovative approach to rapidly producing high-accuracy #LongDNA will enable synthetic biologists to better address some of the world's biggest problems.READ MORE
Listen to our latest podcast on Mendelspod. Matt Hill, the founder and CEO of Elegen describes the inspiration for his new startup and pioneering a new industry for long synthetic DNA using a novel approach.LISTEN
The growing bioeconomy will demand synthetic biology performed on a scale not possible without innovation throughout the DNA and gene synthesis process. Elegen will help the builders in the next evolution of synthetic biology eliminate expensive, time and capital-intensive workflows by using innovative methods and technologies to provide fast-turnaround, high-accuracy, long, synthetic DNA.